Filing Flows › Dare Bioscience (DARE) › Q2 2026
Dare Bioscience (DARE) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Dare Bioscience (DARE) reported revenue of $188K for the second quarter 2026 (Q2 2026) and +23% from the quarter before.
Dare Bioscience, Q2 2026: revenue $188K, net loss $3.0M, operating cash flow −$6.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $188K | +23% | — |
| Operating profit | −$3.0M | — | — |
| Net earnings | −$3.0M | — | — |
| Operating cash flow | −$6.8M | — | — |
What changed
Revenue was $188K in Q2 2026, up 23% from the previous quarter.
Operating costs exceeded revenue by $3.0M, an operating margin of -1582.5%. The quarter ended with a net loss of $3.0M, narrower than the previous quarter's $3.0M loss.
Operating cash flow was −$6.8M. Non-cash charges added back $572K of depreciation and amortization and $287K of share-based compensation. Working capital and other items used $4.7M. Capital expenditures of $81K exceeded it, leaving free cash flow of −$6.9M.
Questions
What was Dare Bioscience's revenue in the second quarter 2026?
Dare Bioscience (DARE) reported revenue of $188K for the second quarter 2026 (Q2 2026) and +23% from the quarter before.
Source: Dare Bioscience 10-Q on SEC EDGAR.